Moderna AI Adoption Tracker
Last updated: April 30, 2026
Overview
Moderna has positioned itself as a leader in AI-driven biotechnology, leveraging artificial intelligence across its entire value chain from drug discovery to manufacturing and commercialization [1]. Beginning with its collaboration with OpenAI in early 2023, the company launched mChat, an internal AI chatbot that achieved over 80% employee adoption [2]. This success led to the deployment of ChatGPT Enterprise across Moderna's 5,000-person workforce, resulting in over 3,000 custom GPTs and 1 million monthly AI interactions as of December 2024 [3]. The company has taken the unprecedented step of merging its HR and IT departments under Chief People and Digital Technology Officer Tracey Franklin, treating AI models as collaborative partners alongside human employees [4].
AI Maturity Index
Radar Comparison
Peer Comparison: Moderna vs healthcare
Based on 66 companies in sector
| Dimension | Moderna | Sector Avg | Diff |
|---|---|---|---|
| Adoption | 5.0 | 3.7 | +1.3 |
| Proficiency | 5.0 | 3.5 | +1.5 |
| Impact | 4.0 | 3.6 | +0.4 |
| Overall | 4.6 | 3.6 | +1.0 |
AI Hiring Signals
Moderna Job Postings Analysis
Tech vs Non-Tech AI Requirements
Non-tech AI adoption exceeds tech roles - strong org-wide AI fluency signal
Top Departments by AI Mention Rate
Analysis
Moderna shows remarkable organizational AI fluency with 14.8% of all job postings mentioning AI. Notably, non-tech roles show 18% AI mention rate compared to only 3.8% for tech roles, indicating AI skills are becoming a core competency across business functions rather than confined to technical teams.
View Sample Job Postings (8 sources)
Key Metrics
AI Initiatives
Benchling R&D Platform Partnership
May 7, 2025
Collaboration to create unified, AI-ready research and development digital platform
Expanded collaboration bringing hundreds of scientists onto integrated platform for experiment design, sample tracking, and results analysis. Enables custom workflow development and integration of proprietary machine learning models.
OpenAI Partnership and mChat Deployment
April 24, 2024
Strategic collaboration with OpenAI to integrate generative AI throughout Moderna's operations
Launched mChat in May 2023, achieving 80% internal adoption. Deployed ChatGPT Enterprise with over 750 initial GPTs across business functions. Partnership expanded to include 4,500 monthly active users and 1,600 custom GPTs by December 2024.
Dose ID GPT
2024
AI-powered clinical decision support tool for vaccine dose optimization
Uses ChatGPT Enterprise's Advanced Data Analytics to evaluate optimal vaccine doses selected by clinical study teams. Applies standard dose selection criteria and generates informative charts, allowing detailed human-led review augmented with AI input while prioritizing safety.
HR-IT Department Merger
2024
Organizational restructuring combining human resources and information technology under single leadership
Created Chief People and Digital Technology Officer role under Tracey Franklin, enabling 'work planning' rather than traditional 'workforce planning' by optimizing mix of human employees and AI agents across functions.
Frequently Asked Questions
Moderna uses AI across its entire value chain, from mRNA sequence optimization and protein design to clinical trial operations, manufacturing procedures, and commercial outreach. Key applications include the Dose ID GPT for vaccine dose selection and automated workflow processing through custom GPTs.
Moderna partners with OpenAI to deploy ChatGPT Enterprise across its 5,000-person workforce. The collaboration began in 2023 with mChat and has expanded to over 3,000 custom GPTs, enabling AI-augmented work in every business function from research to manufacturing.
Over 80% of Moderna's workforce actively uses AI tools, with 4,500 monthly active ChatGPT Enterprise users as of December 2024. The company has achieved organization-wide AI adoption through its AI Academy training program and democratized access approach.
Moderna merged HR and IT to optimize the integration of human employees and AI agents as collaborative partners. This enables 'work planning' rather than traditional workforce planning, allowing tasks to be allocated based on whether they should be automated, augmented, or performed by humans.
Moderna achieved $2 billion in operating cost reductions in 2025, partially attributed to AI-driven efficiency gains. The company targets additional cost savings through AI automation while maintaining its ambitious pipeline of 15 new products over five years with its current workforce.
In Application
| Application | Vendor | Use Case |
|---|---|---|
| ChatGPT Enterprise | OpenAI | Company-wide AI assistant platform enabling custom GPT creation across all business functions from legal to manufacturing |
| mChat | Moderna/OpenAI | Internal AI chatbot built on OpenAI's API for general employee productivity and workflow automation |
| Dose ID GPT | Moderna/OpenAI | Clinical decision support for vaccine dose optimization using advanced data analytics |
| Benchling Platform | Benchling | AI-integrated R&D platform for experiment design, sample tracking, and automated workflow processing |
Sources
Accelerating the development of life-saving treatments
Moderna and OpenAI Collaborate To Advance mRNA Medicine
2024 Annual Report
Moderna's human/AI revamp - will Chief People Officers become the new CIOs?
Our Journey to Becoming a Real-Time AI Organization
Related Companies
About AI Tracker
AI Tracker is a research project by Larridin, the AI execution intelligence platform.
Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.
Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.